GLP-1 Agonists
60 articles on GLP-1 Agonists, written by Shotlee and medically reviewed for clinical accuracy.
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
Greg Davies Ozempic Weight Loss: Key Lessons for GLP-1 Users
Comedian Greg Davies reveals the physical and psychological effects of stopping Ozempic after significant weight loss, offering insights for patients on peptide therapy.
6 min read
Beyond Ozempic: Kris Jenner's Peptide Therapy Journey
Kris Jenner reveals her embrace of peptide therapy, detailing its benefits for energy and skin, and how it served as an alternative to GLP-1 medications like Ozempic. Explore the growing world of peptide treatments.
6 min read
GLP-1 Drugs Fuel Surge in Whey Protein Demand: Industry Response
The massive adoption of GLP-1 receptor agonists for weight management is creating a significant ripple effect across the food industry, specifically driving an intense surge in demand for high-quality, muscle-preserving protein sources like whey. Dairy producers are scrambling to meet this new market reality.
6 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Understanding the Mounjaro (Tirzepatide) PBS Standoff and What It Means for Patients
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
6 min read
GLP-1s Don't Work for Everyone: What to Know If Not Seeing Results
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
7 min read
How to Keep Weight Off After Ozempic: Proven Strategies
Stopping Ozempic often leads to weight regain—up to 7% in trials or two-thirds within a year. While continuing semaglutide helps sustain losses, lifestyle changes and maintenance dosing offer alternatives. Work with your healthcare team for a personalized plan to keep the weight off long-term.
6 min read
IPM Growth Accelerates to 10.1% as GLP-1 Generics Reshape India's Anti-Diabet...
India's pharmaceutical market (IPM) surged 10.1% year-on-year in March 2026, with anti-diabetic therapies leading at 15.5% growth thanks to generic semaglutide entries. The GLP-1 agonist segment exploded to Rs 15.8 billion in MAT March, nearly tripling YoY. Ind-Ra forecasts sustained 9-10% IPM growth in FY27 amid chronic therapy dominance.
4 min read
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
New Study: Why Ozempic Works Better for Some Due to Genetics
Ozempic and similar weight-loss drugs like tirzepatide work better for some patients due to specific genetic variants affecting GLP-1 and GIP receptors, a new 23andMe study shows. While average users lose 10% body weight, those with certain gene copies shed up to 1.5kg more—or face higher nausea and vomiting risks. This research uncovers why responses vary widely.
5 min read
Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy
A prominent cardiologist has filed a whistleblower lawsuit against UPMC alleging racist texts and CEO conflicts. Meanwhile, U.S. blood pressure control remains below pre-pandemic levels, per new data. GLP-1 drugs during pregnancy show promising maternal benefits with no rise in fetal risks, according to a meta-analysis.
6 min read
Doctors Warn: Wedding Weight-Loss Jabs Cause 'Ozempic Face'
Young people are turning to semaglutide and tirzepatide for rapid weight loss before weddings, but doctors warn of 'Ozempic face'—a gaunt, prematurely aged appearance from excessive facial fat and muscle loss. Experts like Dr. Ajaya Kashyap share real cases requiring corrective treatments. Understand the trend, risks, and why medical supervision is essential.
6 min read
Why Fitness Bros Are Buzzing About Retatrutide Weight-Loss Peptide
Fitness enthusiasts and longevity experts are raving about Retatrutide, the new triple-agonist weight-loss peptide dubbed 'the ultimate good' by influencers. Outshining GLP-1 drugs like Ozempic, it targets three receptors for superior fat reduction. As phase 3 trials advance toward FDA approval, here's why it's generating massive buzz.
6 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
Man Wanted for Stealing £12k Mounjaro After Court No-Show
A 27-year-old man from Wigan is being hunted by police after failing to appear in court on charges of stealing over £12,000 worth of Mounjaro weight loss injections from his workplace. The theft highlights the skyrocketing demand for this GLP-1 medication used for type 2 diabetes and appetite control. Understand the case details and what makes Mounjaro so sought after.
4 min read
Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry
Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.
4 min read
FDA Approves Foundayo: GLP-1 Weight Loss Pill with Fewer Use Restrictions
Eli Lilly's Foundayo, a new GLP-1 weight loss pill, just received FDA approval with key advantages: take it anytime without food or water restrictions. Backed by trials showing 12% body weight loss over 72 weeks, it aims to make obesity treatment more accessible. Compare pricing, side effects, and how it stacks up against Wegovy and injectables.
5 min read
India Issues Guidelines on GLP-1 Drugs Use, Risks, Regulations
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
6 min read
How Layla Taylor Got GLP-1 in Utah: Eating Disorder Warning
Reality star Layla Taylor shares her concerning experience obtaining a GLP-1 prescription with alarming ease in Utah, revealing how the medication became an 'unhealthy crutch' amid her long-term battle with an eating disorder. Her story highlights critical gaps in patient screening and mental health considerations.
7 min read
What Happens to Your Body on Ozempic Without Exercising: Study Insights
Wondering what happens to your body when you take Ozempic without exercising? A recent study in Sports Medicine analyzed liraglutide users and found that while GLP-1 drugs promote weight loss, skipping exercise leads to poorer fitness outcomes. Exercise plus the drug delivers the best results for health and function.
5 min read
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
'Ozempic Teeth': Dentists Urge Awareness of Weight Loss Drug Oral Risks
Weight loss drugs like Ozempic are transforming bodies, but dentists are sounding the alarm on 'Ozempic teeth'—a pattern of dry mouth, tooth sensitivity, and gum problems. Lt. Gen Dr Vimal Arora of Clove Dental notes increased xerostomia, dental caries, and early periodontal inflammation among users. Discover why this happens and steps to safeguard your smile.
4 min read
GLP-1 Therapies: Risks and Rewards Across Conditions
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
5 min read
Telangana Warns on Semaglutide Misuse for Weight Loss
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
5 min read
1 in 10 Wegovy and Ozempic Users Lose Less Than 5% Body Weight
Trials show one in ten people on Wegovy and Ozempic lose less than 5% of their body weight, challenging the drugs' reputation as a universal solution. Patient experiences like Samantha Jess's highlight non-responder realities, while experts explain genetic and metabolic factors. Discover why GLP-1 agonists work for some but not others.
6 min read
Savannah Chrisley's Weight-Loss Journey: Liposuction to GLP-1s
Savannah Chrisley, star of 'Chrisley Knows Best,' opened up on her podcast 'Unlocked' about her weight-loss journey, including liposuction and plans to restart GLP-1 medications. After weight gain from endometriosis treatment, she's embracing transparency. Explore the full details and what GLP-1s mean for metabolic health.
5 min read
Ozempic at Oscars 2026 Red Carpet: Is Skinny Back?
At the Oscars 2026 red carpet, an overwhelming uniformity of extremely slender bodies and sunken cheeks dominated, raising questions about Ozempic and GLP-1 agonists. Celebrities like Demi Moore, Emma Stone, and Oprah Winfrey appeared dramatically thinner, contrasting the body positivity era. Is Hollywood reverting to 'heroin chic' aesthetics?
5 min read
Zydus, Lupin Partner to Launch Ozempic Rival Semaglutide in India
Zydus Lifesciences and Lupin are teaming up to bring Semaglutide injection to India, positioning it as a rival to Ozempic for type 2 diabetes and chronic weight management. Marketed by Zydus with a user-friendly reusable pen, this GLP-1 therapy offers new options for adults with poor glycemic control or obesity-related conditions. Here's what patients need to know about this launch.
5 min read
Demi Moore's Slimmer Look Sparks Ozempic Speculation
Demi Moore turned heads at the South By Southwest festival premiere of 'I Love Boosters!' with her strikingly slim silhouette, accentuated by a daring sleeveless wrap dress. This follows her lean look at the Actor Awards, sparking widespread online speculation about Ozempic use. While unverified, the buzz highlights growing interest in GLP-1 medications like Ozempic for weight loss.
6 min read
Ozempic-Like Shots Curb 'Drug Noise' for Addicts: Insurance When?
GLP-1 drugs like Ozempic are silencing 'drug noise' in addicts, slashing overdoses and ER visits per a massive veterans study. Dr. Ziyad Al-Aly explains how these shots target brain reward systems. But FDA approval and insurance coverage remain years away—here's what patients need to know.
5 min read
Sex-Specific GLP-1 Brain Atlas Reveals Drug Impact Differences
A new peer-reviewed study from Mount Sinai researchers has created the first sex-specific atlas of GLP-1 expression in the mouse brain, revealing dramatic differences between males and females. These insights into drugs like semaglutide and liraglutide could reshape treatments for obesity, diabetes, and even psychiatric disorders. Key hindbrain and olfactory bulb variations highlight why GLP-1 effects on appetite and weight loss differ by sex.
5 min read
Study: GLP-1s Reduce Addiction Risks Beyond Weight Loss
A groundbreaking study in the British Medical Journal reveals that GLP-1 drugs like Ozempic offer benefits far beyond weight loss and diabetes control—they significantly reduce risks of alcohol, tobacco, cannabis, and cocaine abuse. Among 606,434 US veterans with type 2 diabetes, these medications lowered substance abuse risks by up to 20%. Experts caution that while promising, more research is needed.
5 min read
Study: GLP-1 Drugs May Fight Addiction Across Major Substances
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
5 min read
Ozempic May Lower Addiction Risk, New BMJ Study Shows
A groundbreaking BMJ study reveals GLP-1 drugs like Ozempic may reduce the risk of developing substance use disorders by 14% in diabetes patients. Among those with existing addictions, hospital admissions dropped 26%. While promising, these are associations from veteran health records—randomized trials are needed for proof.
5 min read
Is Oprah Winfrey Taking Ozempic? Paris Fashion Week Sparks Buzz
Oprah Winfrey turned heads at Paris Fashion Week with a noticeably slimmer figure, igniting Ozempic speculation across social media. While the 72-year-old host hasn't confirmed using the drug, her recent podcast revelations about GLP-1 medications have fueled the conversation. Dive into the details of her chic appearance and the science of these popular injectables.
6 min read
GLP-1s Curb Cravings Beyond Food: 600K Study Suggests
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
5 min read
GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why
Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.
6 min read
How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism
A Rhode Island mother battled alcoholism for years, losing custody of her son—until GLP-1 drugs like Wegovy changed everything. In a pilot program at Open Doors transitional home, Gina Roberts stopped her cravings, got sober for two years, and rebuilt her life. Addiction specialists share why these weight-loss meds show promise for addiction recovery.
5 min read
Glenmark to Launch Affordable Semaglutide, Joining Indian Peers
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
5 min read
RFK Jr. Plans to Unban 14 FDA-Banned Peptides, Tells Joe Rogan
RFK Jr. revealed on the Joe Rogan Experience his intent to lift FDA restrictions on 14 banned peptides from compounding pharmacies. This reversal addresses the late 2023 Category 2 list ban amid safety concerns and black market shifts. Patients and wellness advocates await formal decisions in coming weeks.
5 min read
Ozempic and Metformin: Similarities After Side Effect Warnings
Ozempic and metformin are both widely used for Type 2 diabetes management, sharing benefits like blood sugar control and potential weight loss effects, but recent side effect warnings highlight their overlaps and differences. While metformin serves 120 million people worldwide as a daily tablet, Ozempic is a weekly injection for adults. Understand why consulting your doctor is essential before switching.
6 min read
Luke Combs on Skipping GLP-1s for Weight Loss: 'Not the Short Way'
Grammy-nominated country singer Luke Combs revealed on The New York Times' Popcast why GLP-1 weight loss drugs aren't for him: he wants to 'beat myself' the hard way. Motivated by his wife and kids, Combs embraces the struggle over quick fixes amid lifelong weight battles. His story highlights the personal choice in pursuing metabolic health.
6 min read
Pfizer's China GLP-1 Deal and BRAFTOVI Oncology Approval
Pfizer is pushing forward on dual fronts: a major $495M deal for Ecnoglutide in China's booming GLP-1 market and full FDA approval for its BRAFTOVI regimen in metastatic colorectal cancer. Clinical data highlights 15.1% placebo-adjusted weight reduction and a 51% drop in mortality risk from the BREAKWATER study. These moves underscore Pfizer's strategy in metabolic and oncology therapeutics.
5 min read
NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
6 min read
Wegovy's Weight Loss Hype Meets Reality: What Americans Should Know
Wegovy's explosion on TikTok and US headlines promises dramatic weight loss, but the reality involves high costs, pharmacy shortages, and the need for medical supervision. As a higher-dose semaglutide GLP-1 agonist approved for obesity, it offers double-digit weight loss in trials—but stopping it often leads to regain. US experts urge viewing it as chronic disease management, not a casual 'slimming trend.'
6 min read
Tirzepatide in Mounjaro Cuts Alcohol Intake Over 50%, Study Shows
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
6 min read
Study: Ozempic, Wegovy NAION Risk Twofold Higher vs. SGLT2i Drugs
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
5 min read
Beware the Peptide Übermensch: Biohacking's New Frontier
In Manhattan medspas and Bushwick fridges, peptides are fueling a quest for the perfect body—from GLP-1 pens vanquishing appetite to experimental vials promising telomere extension. But as biohackers chase the peptide Übermensch, what hidden costs lurk in this shift from treating illness to perfecting the self? Discover the cultural frenzy, market divides, and societal stakes.
4 min read
How GLP-1 Weight Loss Drugs Revolutionized Obesity: Lessons Learned
GLP-1 weight loss drugs such as Wegovy and Zepbound have revolutionized obesity care, leading to up to 20% body weight reduction over 72 weeks. These therapies challenge old views of obesity as mere lifestyle failure, highlighting brain hunger centers, genetics, and hormones. From chronic disease recognition to equitable access, here's how they've reshaped treatment.
5 min read
Founder Targets $50B GLP-1 Market with Natural Alternative
In a $50 billion GLP-1 market dominated by injectables like Ozempic, Becca McCarthy is carving out space with Evolv—a natural pill for appetite control. Teaming with a molecular biologist, she's delivering GLP-1-like effects without stigma or synthetics. Here's how she's challenging the prescription-only model.
5 min read
GLP-1 Envy Was Just the Beginning: Hims & Hers Super Bowl Ad
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
5 min read
New GLP-1 Weight-Loss Drugs Stronger Than Wegovy and Zepbound
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
8 min read
Ozempic's Wall Street Effect: Tailors Witness Epic Weight Loss
Wall Street tailors are busier than ever, altering suits for clients who've shed 20-30 pounds on Ozempic and similar GLP-1 drugs. This surge reflects the real-world impact of these medications, with studies showing up to 15% body weight loss. Explore the science behind it and how to maximize benefits safely.
4 min read
Peptide Therapy Guide: GLP-1s, Benefits & Risks
Peptide therapy has surged in popularity, driven by GLP-1 drugs like Ozempic and Wegovy that transform weight management and metabolic health. This guide breaks down the science, approved uses, potential benefits, and critical risks. Gain evidence-based insights to make informed decisions.
4 min read
GLP-1 Medications: Patient Stories, Science & Real Risks
GLP-1 medications like Zepbound have transformed lives, helping patients lose significant weight amid personal challenges. But rapid results come with risks like gallstones and muscle loss. This guide blends real stories with clinical insights for informed decisions.
4 min read
Swift Weight Rebound and Erosion of Health Advantages Upon Discontinuing GLP-1s
Individuals regain their initial weight and shed all cardiometabolic improvements in less than two years following the cessation of semaglutide or tirzepatide, according to a comprehensive meta-analysis. The research underscores the rapid nature of this regain, occurring at a pace much quicker than after non-medication interventions. Experts stress the importance of sustained strategies for maintaining benefits in chronic obesity treatment.
6 min read
Roche Allocates $100 Million in Structure Licensing Pact to Bolster GLP-1 Standpoint
Roche has invested $100 million in a licensing agreement with Structure Therapeutics to protect its GLP-1 portfolio from patent challenges. The deal covers CT-996, an oral GLP-1 medication acquired from Carmot, and includes royalties on future sales. Analysts highlight how this move reinforces Structure's strong intellectual property in GLP-1 agonists.
3 min read
GLP-1 Breakthrough: Mazdutide Outperforms Semaglutide for Weight Loss & Diabetes
New research shows that Mazdutide may be superior to Semaglutide (Ozempic/Wegovy) for weight loss and improved blood sugar control. Learn about this exciting development and what it means for the future of diabetes and weight management.
3 min read
GLP-1s & Hollywood: Decoding Clooney's Weight Loss Transformation
George Clooney's recent appearance sparked concerns about his health, with many attributing his weight loss to GLP-1 drugs like Ozempic. This raises important questions about the use of these medications and their impact on overall wellness and longevity.
3 min read